Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01643460 · ClinicalTrials.gov registry record · NA
Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
A NA study of Pancreatic Cyst and Pancreatic Intraductal Papillary Mucinous Neoplasm, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01643460: Completed NA study of Pancreatic Cyst and Pancreatic Intraductal Papillary Mucinous Neoplasm, sponsored by Indiana University.
NCT01643460 is a NA study of Pancreatic Cyst and Pancreatic Intraductal Papillary Mucinous Neoplasm that has completed, run by Indiana University. The registered enrollment target is 33 participants, below the 548-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01643460, a NA study of Pancreatic Cyst and Pancreatic Intraductal Papillary Mucinous Neoplasm, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to track outcomes and complications of patients at IUMC referred by physicians for EUS-guided pancreatic cyst ablation. This information is essential in order to disseminate future published information to physicians about this technique. A database will be created to track these patients undergoing an already scheduled/planned procedure. Phone calls at selected intervals will be made following the procedure to track any complications that occur
Primary Outcome
1\. Patients will undergo EUS-guided cyst ablation with ethanol +/- paclitaxel as indicated for their scheduled procedure. 2. Patients will return 3 months after initial ablation for a repeat EUS, and ablation will be repeated if cyst size is \>10mm in diameter. 3. CT or MRI imaging will be performed 3 months after the second procedure to assess for cyst resolution.
Conditions Studied
Interventions
- PROCEDURE 98% Ethanol & Paclitaxel injection
Study Locations (1)
Indiana
- Indiana University Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-09 |
| Est. Completion | 2022-03-31 |
| Phase | NA |
What the finished NCT01643460 record still lists
NCT01643460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 548-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Pancreatic Cyst appearing as the primary indexed condition, and to 1 intervention - of which 98% Ethanol & Paclitaxel injection is the first listed.
NCT01643460 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT01643460 about?
NCT01643460 is a clinical study titled "Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts". The purpose of this study is to track outcomes and complications of patients at IUMC referred by physicians for EUS-guided pancreatic cyst ablation. This information is essential in order to disseminate future published information to physicians about this technique. A database will be created to tr...
What is the current status of trial NCT01643460?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2009-09. Estimated completion is 2022-03-31.
What conditions does trial NCT01643460 study?
This clinical trial studies the following conditions: Pancreatic Cyst, Pancreatic Intraductal Papillary Mucinous Neoplasm, Cystadenoma, Mucinous, Papillary Mucinous Cystadenoma, Borderline Malignancy.
What interventions are being tested in trial NCT01643460?
The interventions under investigation include: 98% Ethanol & Paclitaxel injection (PROCEDURE).
Who is sponsoring clinical trial NCT01643460?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01643460 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cyst
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01643460's enrollment target sits among peer trials
33 16th of 18 higher than 3 of 18 other Pancreatic Cyst trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cyst trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies
RECRUITING · NA
-
Cyst Fluid Glucose for On-site Diagnosis of Mucinous Pancreatic Cysts
COMPLETED · NA
-
Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
RECRUITING
-
UCSF PANC Cyst Registry
RECRUITING
-
PROMs After Pancreatectomy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia